

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: U.S. Patent and Trademark Office, P.O. BOX 2327, ARLINGTON, VA 22202 ON THE DATE INDICATED BELOW.

BY: Victoria A. Jones

DATE: 9/5/02



**PATENT**  
**BOX SEQUENCE**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Patent Application of : Group Art Unit 1644  
Jürgen Eck et al. :  
:  
:  
Conf. No.: 3271 :  
:  
Appln. No: 09/347,064 : Examiner: Margaret Jamroz  
:  
Filed: July 2, 1999 :  
:  
Title: Nucleic Acids Encoding Fusion Proteins : Attorney Docket  
Based on Ribosome-Inactivating Proteins of : No. **9282-5**  
the Mistletoe *Viscum Album* : **(B 3521 US)**  
:

**RECEIVED**  
**SEP 12 2002**  
**TECH CENTER 1600/2900**

**STATEMENT TO SUPPORT FILING AND SUBMISSION**  
**IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825**

I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a), included in the replacement Sequence Listing are supported in the application, as filed, at least at page 25, and Figure 11c.

I hereby state that the replacement Sequence Listing does not include new matter.

I hereby state that the replacement copy of the Sequence Listing in computer readable form, submitted herewith in accordance with 37 C.F.R. § 1.825(b), is the same as the replacement paper copy of the Sequence Listing.

Respectfully submitted,

**JÜRGEN ECK et al.**

5 September 2002  
(Date)

By: Kristyne A. Bullock

**KRISTYNE A. BULLOCK**

Registration No. 42,371

**AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.**

One Commerce Square

2005 Market Street - Suite 2200

Philadelphia, PA 19103-7086

Telephone: (215) 965-1200

**Direct Dial: (215) 965-1348**

Facsimile: (215) 965-1210

E-Mail: [kbullock@akingump.com](mailto:kbullock@akingump.com)


Attorney for Applicants

KAB/vj

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



**COPY**

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: see attachment

**RECEIVED**  
SEP 12 2002  
TECH CENTER 1600/2900

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**